OncoZenge (ONCOZ) Q1 2026 earnings summary

Executive summary

• Regulatory acceptance received for Phase III trial of BupiZenge™; full EMA approval expected by May 29, 2026, with patient recruitment planned for Q2 2026.

• Third investment tranche from Yangtian Pharma received; further milestone payments expected upon CTA approval, boosting liquidity by SEK 30 million since year start.

• Operational readiness maintained through bridge financing from Linc AB to support trial initiation.

• BupiZenge™ targets pain relief for oral mucositis in cancer patients, addressing significant unmet needs and aiming to reduce opioid use.

Financial highlights

• Net sales for Q1 2026 were SEK 0 thousand, down from SEK 2,713 thousand in Q1 2025.

• Operating result was SEK -6,802 thousand (Q1 2025: SEK 44 thousand); result after tax was SEK -7,132 thousand.

• Cash flow for the period was SEK -2,779 thousand; cash and cash equivalents at period end were SEK 935 thousand.

• Equity ratio dropped to 3.03% from 34.74% at year-end 2025.

Outlook and guidance

• Patient enrollment for Phase III trial expected to begin in Q2 2026, pending final EMA approval.

• Additional milestone payments and investment tranches anticipated in Q2 2026 to further strengthen liquidity.

• Board and CEO assess sufficient liquidity for at least twelve months, assuming planned financing is secured.